October 22, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Eisai Launches Programs to Help Eliminate Lymphatic Filariasis By 2020
 

Tokyo, Jan 31, 2012 (JCN) - In line with its commitment to support the World Health Organization's lymphatic filariasis elimination program, Eisai Co., Ltd, as one of the 13 major research and development-based pharmaceutical companies, the Bill & Melinda Gates Foundation, the U.S. and U.K. governments, the World Bank and governments from neglected tropical disease (NTD)-endemic countries, gave its support on January 30 (local London time) to the London Declaration, a coordinated effort to eliminate 10 NTDs by the end of this decade.

Eisai is committed to taking proactive steps to address issues related to access to medicines, including NTDs, in accordance with established policy as it expands its business in both emerging and developing nations in this era of great globalization. The company considers its contributions to the economic development and expansion of the middle-income class through the enhancement of health and welfare in these countries as a form of long-term investment for future growth.

Eisai is the only Japanese company to join this coordinated program. In support of the London Declaration and the WHO's program to eliminate lymphatic filariasis, Eisai has signed an agreement with the WHO to extend its support until 2020, during which Eisai will supply free of charge 2.2 billion tablets of the medicine DEC (diethylcarbamazine) until 2020, in line with the WHO elimination goals.

Eisai will start manufacturing DEC in accordance with the high quality standards of WHO at its plant in Vizag, India, and provide it to people in need as a price "zero" Eisai product, while working on the collection and provision of relevant safety information to ensure the appropriate use of the medicine. Eisai will begin supplying DEC from 2013, and plans to deliver this medicine to some 250 million people in the developing world by 2020.

Eisai has also committed to provide 120 million DEC tablets to the WHO free of charge in collaboration with Sanofi and the Bill & Melinda Gates Foundation to ensure a stable of supply of DEC until 2013 when the Eisai-produced DEC becomes available. This is the first partnership in which two pharmaceutical companies, with the Gates Foundation, have come together to supply a single drug for an NTD.

By Chris Lui Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Eisai News  
  U.S. FDA Accepts sNDA For Antiepileptic Agent Fycompa as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures  (Oct 21, 2014)
  U.S. FDA Grants Priority Review Status to NDA for Anticancer Agent Lenvatinib  (Oct 15, 2014)
  U.S. FDA Accepts Eisai's sNDA for BANZEL (Rufinamide) as Adjunctive Treatment in Pediatric Patients With Lennox-Gastaut Syndrome  (Oct 15, 2014)
  U.S. FDA Approves Antiemetic Agent Akynzeo For Prevention Of Chemotherapy-Induced Nausea and Vomiting (CINV)  (Oct 14, 2014)
  Eisai Launches Anti-Cancer Agent Halaven in Australia  (Oct 1, 2014)
  Phase III Trial of Aricept in Patients with Severe Alzheimer's Disease in China Meets Primary Endpoint  (Sept 30, 2014)
  Aricept Approved In Japan As Treatment For Dementia With Lewy Bodies  (Sept 19, 2014)
  Plasmacluster Ion Technology Reduced Airway Inflammation in Pediatric Patients with Mild to Moderate Atopic Asthma  (Sept 18, 2014)
  Eisai to Present Latest Clinical Data on Halaven(R) (Eribulin) and Lenvatinib at 39th ESMO Congress  (Sept 17, 2014)
  Eisai Enters Two Joint Research Agreements to Develop New Antimalarial Medicines  (Sept 16, 2014)



 Recent  Drugs & OTC News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Drugs & OTC news...

 Recent  Medical News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Medical news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)